Two NEW companion diagnostic tests to meet your oncology challenges
We continue to innovate and collaborate to offer the first companion diagnostic tests for AML patients with IDH1 & IDH2 mutations. Our new test offerings have proven accuracy and sensitivity that helps to identify AML patients that could benefit from new treatments and the effective use of the targeted drugs TIBSOVO® (ivosidenib) and IDHIFA® (enasidenib).
NEW! IDH1 Abbott Realtime PCR test (Test Code: 7647)
This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib). Learn More.
NEW! IDH2 Abbott Realtime PCR test (Test Code: 7648)
This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-2 (IDH2) mutation for treatment with IDHIFA® (enasidenib). Learn More.
Molecular Oncology Survey
To better serve hospitals and physicians with patient treatment, we would like your input again regarding Hematologic Oncology Sequencing testing. To aid in providing this input, we are conducting a brief survey. The questionnaire should take less than two minutes to complete.
Complete Our Short Survey
Versiti provides innovative diagnostic and prognostic testing in blood cancers to support patient stratification and therapeutic decisions. We deliver novel testing services that provide critical clinical direction in complex cases of acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and chronic myelogenous leukemia (CML). Our testing menus are built around testing algorithms as recommended by the National Comprehensive Cancer Network (NCCN) and the World Health Organization (WHO).